<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02750579</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A00379-42</org_study_id>
    <nct_id>NCT02750579</nct_id>
  </id_info>
  <brief_title>Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?</brief_title>
  <official_title>Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percutaneous coronary intervention (PCI) is the cornerstone of the care of intermediate and&#xD;
      high-risk non ST-elevation acute coronary syndromes (NSTE ACS). Revascularization reduces the&#xD;
      rate of cardiovascular death and recurrent myocardial infarction in this clinical setting.&#xD;
      The recommendation regarding the timing of intervention in this clinical setting is derived&#xD;
      from old trials and has a weak level of evidence. In fact, there are no conclusive randomized&#xD;
      trials in the contemporary era providing guidance on the optimal timing of intervention. In&#xD;
      addition, the optimal timing of this critical intervention has not been studied since the&#xD;
      development of new P2Y12-ADP receptor antagonists and the controversy surrounding the use of&#xD;
      pretreatment with a P2Y12-ADP receptor antagonist before intervention. Early intervention in&#xD;
      intermediate and high-risk non ST-elevation ACS is not well validated to date. In addition,&#xD;
      the recent changes in the use of pretreatment with P2Y12-ADP receptor antagonists may impact&#xD;
      on the potential benefit of an early intervention.&#xD;
&#xD;
      Based on these evidences, we hypothesize that with the current protocols of care without&#xD;
      pretreatment with a P2Y12-ADP receptor antagonist, an early PCI (&lt;2 hours) would be superior&#xD;
      to a delayed (between 12 to 72 hours) PCI in the setting of intermediate or high-risk non-ST&#xD;
      elevation acute coronary syndrome to prevent cardiovascular death and ischemic recurrences.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 5, 2016</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recurrent ischemic events</measure>
    <time_frame>1 month</time_frame>
    <description>compare the efficacy defined by the rate of recurrent ischemic events at 1 month of 2 therapeutic strategies: an immediate (&lt;2 hours) versus a delayed (12-72 hours) intervention for intermediate and high-risk non ST-elevation acute coronary syndrome compare the efficacy defined by the rate of cardiovascular death and/or recurrent ischemic events at 1 month of 2 therapeutic strategies: an immediate (&lt;2 hours) versus a delayed (12-72 hours) intervention for intermediate and high-risk non ST-elevation acute coronary syndrome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cardiovascular death</measure>
    <time_frame>1 month</time_frame>
    <description>compare the efficacy defined by the rate of cardiovascular death at 1 month of 2 therapeutic strategies: an immediate (&lt;2 hours) versus a delayed (12-72 hours) intervention for intermediate and high-risk non ST-elevation acute coronary syndrome</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">740</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control group: Percutaneous coronary intervention for revascularization delayed intervention (12 to 72 hours)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>experimental group: early Percutaneous coronary intervention for revascularization intervention (&lt;2 hours)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous coronary intervention for revascularization</intervention_name>
    <description>Percutaneous coronary intervention for revascularization with anticoagulant and antiplatelet therapy (routine care)</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must not be of child-bearing potential (1 year post-menopausal, contraceptive use or&#xD;
             surgically sterile);&#xD;
&#xD;
          -  Subject with a non-ST-segment elevation ACS defined by the presence of at least 2 of&#xD;
             the following criteria: symptoms of myocardial ischemia, electrocardiographic&#xD;
             ST-segment abnormalities (depression or transient elevation of at least 0.1 mV) or&#xD;
             T-wave inversion in at least in 2 contiguous leads, or an elevated cardiac troponin&#xD;
             value (above the upper limit of normal) ;&#xD;
&#xD;
          -  Subject requiring intervention according to physician's judgment including the&#xD;
             following criteria subject with one of the following risk factor defining intermediate&#xD;
             and high risk ACS: diabetes mellitus, kidney failure, reduced LVEF, early post&#xD;
             infarction angina, recent PCI, prior CABG or a GRACE risk score &gt;109, recurrent&#xD;
             symptoms or ischaemia on non-invasive testing (2);&#xD;
&#xD;
          -  Must be enrolled at a cardiac catheterization laboratory hospital or at a&#xD;
             hospital/ambulance service affiliated with a cardiac catheterization laboratory&#xD;
             hospital;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Minors or pregnant or breast-feeding women;&#xD;
&#xD;
          -  Subject with low risk ACS;&#xD;
&#xD;
          -  Subject with very high-risk ACS: refractory angina, severe heart failure,&#xD;
             life-threatening ventricular arrhythmias, hemodynamic instability requiring immediate&#xD;
             intervention;&#xD;
&#xD;
          -  Subject with thrombolytic therapy during the preceding 24 hours;&#xD;
&#xD;
          -  Subject with bleeding diathesis;&#xD;
&#xD;
          -  Subject with Upstream treatment by a GPIIb/IIIa inhibitor;&#xD;
&#xD;
          -  Subject under chronic anticoagulant;&#xD;
&#xD;
          -  Subject participating in another research protocol;&#xD;
&#xD;
          -  Subject not agreeing to participate;&#xD;
&#xD;
          -  Subject with contraindication to or under chronic P2Y12 receptor antagonists therapy&#xD;
             (clopidogrel, ticagrelor and prasugrel);&#xD;
&#xD;
          -  Present with ST-segment elevation myocardial infarction (STEMI) at the time of entry&#xD;
             or randomization into the study defined as follows:&#xD;
&#xD;
          -  ST-segment elevation myocardial infarction is defined as a history of chest discomfort&#xD;
             or ischemic symptoms of &gt;20 minutes duration at rest ≤14 days prior to entry into the&#xD;
             study with one of the following present on at least one ECG prior to randomization:&#xD;
&#xD;
               1. ST-segment elevation ≥1 mm in two or more contiguous ECG leads.&#xD;
&#xD;
               2. New or presumably new left bundle branch block (LBBB).&#xD;
&#xD;
               3. ST-segment depression ≥1 mm in two anterior precordial leads (V1 through V4) with&#xD;
                  clinical history and evidence suggestive of true posterior infarction.&#xD;
&#xD;
          -  Have cardiogenic shock (systolic blood pressure &lt;90 mm Hg associated with clinical&#xD;
             evidence of end-organ hypoperfusion, or subjects requiring vasopressors to maintain&#xD;
             systolic blood pressure over 90 mm Hg and associated with clinical evidence of&#xD;
             end-organ hypoperfusion);&#xD;
&#xD;
          -  Have New York Heart Association (NYHA) Class IV congestive heart failure (CHF).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Bonello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>assistance Public Hopitaux de Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 21, 2016</study_first_submitted>
  <study_first_submitted_qc>April 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

